Swedish health-tech company Brighter AB (Nasdaq First North Growth Market:BRIG) said on Wednesday that it has signed an agreement with the Northern Care Alliance NHS Foundation Trust in the UK for a funded-research study with Actiste Diabetes Management as a Service (ADMS) in the city of Salford.
This study is a high-level clinical-research project that the company hopes will confirm scientifically relevant insights about the benefits that Actiste can provide for the management of both type 1 and type 2 insulin-treated diabetes.
The research data will be shared with the diabetes scientific community, front-line care providers, patients, health-insurance companies and partners.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients